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background:  Atrial fibrillation (AF) carries an increased risk of stroke and death that is significantly reduced by oral anticoagulant (OAC). 
Stroke is reduced 64% and death 26% in meta-analyses of randomized controlled trials, but it is uncertain whether residual risk returns to 
that of non-AF controls.
Methods:  Cohort study of incidental asymptomatic AF between 2001-2009 followed 3 years using UK CPRD, linked with hospital 
discharge diagnoses, causes of death and prescriptions. We included 5,555 patients aged < 85 (mean age 70.9±10.1), seen in general 
practice and not hospitalized, and 24,705 patients without AF matched for age, gender, and AF date. Kaplan-Meier cumulative risk 
(competing risk for stroke) and proportional hazards regression for stroke and all-cause death were used, with adjustment for all 
CHA2DS2VASc elements, smoking, previous major bleed, cancer, prior aspirin and Charlson Comorbidity Index. OAC± aspirin was given 
to 2,492 and 1,460 received no treatment. Proportional hazards assumptions on treatment were fulfilled for 1.5 years only.
results:  Stroke risk at 1.5 years was reduced significantly on OAC by 65%, to a level not different to non-AF controls (Fig). Death was 
reduced significantly by 44% but residual risk remained significantly higher than non-AF controls.
Conclusion:  Absolute risk of both stroke and death 1.5 years after diagnosis of incidental AF is reduced by ~3% with OAC. Incremental 
risk of stroke (but not death) associated with incidental AF can be abolished by OAC.
 
